Nifelat (Nifedipine)

Nifedipine blocks L‑type calcium channels in vascular smooth muscle and cardiac cells. This inhibition prevents calcium entry, reducing muscle contraction and causing vasodilation of peripheral and coronary arteries. The resulting drop in peripheral resistance lowers arterial pressure, while coronary dilation improves oxygen delivery to the heart.

The appropriate dose of Nifelat is determined by the prescribing healthcare professional based on the patient’s condition, response, and other clinical factors. Dosage regimens may differ for hypertension, angina, or Raynaud's phenomenon, and adjustments are made according to therapeutic goals and tolerability.

Safety of nifedipine in pregnancy and lactation has not been definitively established. Physicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their obstetric or primary care provider.

To request Nifelat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nifelat (nifedipine) belongs to the calcium channel blocker class, offering rapid vasodilation and effective blood‑pressure control. Compared with ACE inhibitors or beta‑blockers, it may produce more pronounced peripheral edema but is useful when patients cannot tolerate those classes. Choice of therapy depends on individual comorbidities, side‑effect profiles, and physician preference.

Store Nifelat at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments. Do not use if the packaging is damaged or the tablet appears discolored.

Nifelat is taken orally, usually with a glass of water. It may be taken with or without food, but consistent administration with respect to meals can help maintain stable drug levels. Patients should follow the prescribing clinician’s instructions regarding timing, dosage, and whether the tablet should be swallowed whole or split.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, and life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden weakness, chest pain, yellowing of the skin or eyes, or signs of a severe allergic response.

Nifelat is contraindicated in patients with known hypersensitivity to nifedipine or any other calcium channel blocker. It should also be avoided in individuals with severe aortic stenosis, uncontrolled heart failure, or cardiogenic shock, as the vasodilatory effect may worsen these conditions. Clinicians must assess each patient’s medical history before initiating therapy.